[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100261446":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"1\u002FCohort 1",null,"Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency",[13],{"name":14,"affiliation":15,"role":16},"Scott M Norberg, D.O.","National Cancer Institute (NCI)","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","(301) 275-9668","scott.norberg@nih.gov",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-77.10026,38.98067,{"lat":35,"lon":34},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100261446","biospecimen-procurement-for-center-for-immuno-oncology-immunotherapy-protocols-100261446",false,"NCT02682667","Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","* INCLUSION CRITERIA:\n\n  1. Diagnosis of cancer, a premalignant\u002Fneoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant\u002Fneoplastic condition\n  2. Age \\>=18 years of age\n  3. ECOG performance status of 0-3.\n\n  5\\. Ability and willingness of subject to provide informed consent\n\nAdditional inclusion criteria pertinent only for participants undergoing apheresis\n\n1. Hemoglobin \\>= 8 mg\u002FdL and platelet count \\> 75 K\u002FmicroL\n2. Weight \\>= 48 kg\n3. Central line in place or adequate venous access\n\nEXCLUSION CRITERIA:\n\n1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.\n2. Inability to provide informed consent\n3. Pregnant or breastfeeding women","ALL","18 Years","120 Years",{"count":49,"type":50},500,"ESTIMATED","OBSERVATIONAL","Background:\n\nCancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.\n\nObjective:\n\nTo better understand the biology of malignancies and why certain cancers respond differently to treatment.\n\nEligibility:\n\nAdults at least 18 years old with cancer or a pre-cancerous condition.\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.\n\nParticipants will send tissue blocks or slides from their original tumor biopsy.\n\nAt least once, participants will have a medical history, physical exam, and blood and urine tests.\n\nParticipants may have the following tests. They may have them more than once:\n\nApheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.\n\nBone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.\n\nPiece of cancer tissue taken by a needle and syringe.\n\nComputed tomography (CT) scan, magnetic resonance imaging (MRI) and\u002For positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.\n\nA small piece of skin removed.\n\nParticipants will be contacted by phone once a year to find out how they are doing.",[54,55,56,57,58],"Multiple Myeloma","Lymphoma, Non-Hodgkin","Leukemia-Lymphoma, Adult T-Cell","Hodgkin Disease","Non-Small Cell Lung Cancer",[60,61,62,63,64,65],"Apheresis Products","Immunological","Diverse Malignan","Premalignant","Protein","Natural History","2026-06-23",{"date":68,"type":69},"2026-06-24","ACTUAL",{"date":71,"type":69},"2016-04-11",{"date":73,"type":50},"2032-12-01",{"name":15,"class":6},1]